[
  {
    "ts": "2026-01-21T14:09:23+00:00",
    "headline": "Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness",
    "summary": "Why Gilead Sciences (GILD) Is on Investors’ Radar Today Gilead Sciences (GILD) is drawing investor attention after recent trading left the stock with a 1-day return of about a 1% decline, alongside modest moves over the week and month. See our latest analysis for Gilead Sciences. That small 1 day share price decline sits against a steadier backdrop, with a 7 day share price return of 1.95% and a year to date share price return of 2.09%, while the 1 year total shareholder return of 37.27%...",
    "url": "https://finance.yahoo.com/news/gilead-sciences-gild-valuation-check-140923905.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1a54b7c1-8e8d-394a-bf77-534e2bfb2071",
      "content": {
        "id": "1a54b7c1-8e8d-394a-bf77-534e2bfb2071",
        "contentType": "STORY",
        "title": "Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness",
        "description": "",
        "summary": "Why Gilead Sciences (GILD) Is on Investors’ Radar Today Gilead Sciences (GILD) is drawing investor attention after recent trading left the stock with a 1-day return of about a 1% decline, alongside modest moves over the week and month. See our latest analysis for Gilead Sciences. That small 1 day share price decline sits against a steadier backdrop, with a 7 day share price return of 1.95% and a year to date share price return of 2.09%, while the 1 year total shareholder return of 37.27%...",
        "pubDate": "2026-01-21T14:09:23Z",
        "displayTime": "2026-01-21T14:09:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-valuation-check-140923905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-valuation-check-140923905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T22:00:00+00:00",
    "headline": "New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer",
    "summary": "FOSTER CITY, Calif., January 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). ASCENT-04 successfully met its primary endpoint of progression-free survival (PFS) with a 35% (HR: 0.65;",
    "url": "https://finance.yahoo.com/news/england-journal-medicine-publishes-phase-220000419.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "55d156b4-3cee-32d3-bb00-51c85d1cb5da",
      "content": {
        "id": "55d156b4-3cee-32d3-bb00-51c85d1cb5da",
        "contentType": "STORY",
        "title": "New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer",
        "description": "",
        "summary": "FOSTER CITY, Calif., January 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). ASCENT-04 successfully met its primary endpoint of progression-free survival (PFS) with a 35% (HR: 0.65;",
        "pubDate": "2026-01-21T22:00:00Z",
        "displayTime": "2026-01-21T22:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/1dc294ae2fd49566e043e3df17c809ef",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4yHq.pSeEAh29NS7.F0Yaw--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1dc294ae2fd49566e043e3df17c809ef.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IZ4N4BQx0DUTRgF1QBzJ.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1dc294ae2fd49566e043e3df17c809ef.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/england-journal-medicine-publishes-phase-220000419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/england-journal-medicine-publishes-phase-220000419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]